 |
|
|
|
 |
A Phase II Trial of Irinotecan, Cisplatin, Bevacizumab, and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma
[Protocol 06-013]
- Full Title :
- PHASE II TRIAL OF IRINOTECAN, CISPLATIN, BEVACIZUMAB AND CONCURRENT RADIOTHERAPY IN LOCALLY ADVANCED ESOPHAGEAL ADENOCARCINOMA
- Purpose :
At Memorial Sloan-Kettering, the anticancer drug cisplatin is commonly used in combination with the drug irinotecan, both before and during radiation therapy, to treat patients with locally advanced cancer of the esophagus. However, even with the combination of chemotherapy and radiation therapy, the cancer may continue to grow or may recur in some patients.
The purpose of this study is to evaluate the effectiveness of adding another anticancer drug, bevacizumab, to the combination of irinotecan, cisplatin, radiation therapy, and surgery in patients with locally advanced esophageal cancer. Bevacizumab is used to treat advanced colon cancer, under the name Avastin®. It may prevent the development of the blood vessels that tumors need to grow and spread.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of locally advanced adenocarcinoma of the esophagus (limited to the esophagus or gastroesophageal junction) that is able to be surgically removed.
- Patients may not have had prior radiation therapy or chemotherapy.
- At least 4 weeks must have passed since any major surgery and entry into the study.
- Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Dr. David Ilson at 212-639-8306.
|
|
|
|
|
